Oculis Holding AG (OCS) Free Cash Flow (2022 - 2026)
Oculis Holding AG (OCS) recorded quarterly Free Cash Flow of -$19.6 million in Q1 2026, up 5.99% quarter-over-quarter from -$20.8 million in Q4 2025, and up 7.12% on a YoY basis from -$18.3 million in Q1 2025.
Oculis Holding AG (OCS) Free Cash Flow (2022 - 2026) Analysis & Trends
Oculis Holding AG's Free Cash Flow history runs 5 years deep, the most recent figure standing at -$19.6 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 7.12% year-over-year to -$19.6 million; the TTM figure through Mar 2026 stood at -$77.7 million (down 28.08% YoY), while the FY2025 annual figure was -$82.6 million, down 48.58% from the prior year.
- Free Cash Flow was -$19.6 million for Q1 2026 at Oculis Holding AG, up from -$20.8 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$6.8 million in Q4 2022 to a low of -$21.1 million in Q1 2025.
- Historically, Free Cash Flow has averaged -$15.3 million across 5 years, with a median of -$15.7 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Free Cash Flow plunged 136.64% in 2023, then grew 24.53% in 2024.
- A 5-year view of Free Cash Flow shows it stood at -$6.8 million in 2022, then slumped by 136.64% to -$16.0 million in 2023, then advanced by 24.53% to -$12.1 million in 2024, then tumbled by 72.3% to -$20.8 million in 2025, then increased by 5.99% to -$19.6 million in 2026.
- The last three Free Cash Flow figures came in at -$19.6 million (Q1 2026), -$20.8 million (Q4 2025), and -$16.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 63,220.27 |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - | -19.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.58 Mn |
| Mar 31, 2026 | -19.58 Mn |
| Dec 31, 2025 | -20.82 Mn |
| Dec 31, 2025 | -20.82 Mn |
| Sep 30, 2025 | -16.62 Mn |
| Sep 30, 2025 | -16.62 Mn |
| Jun 30, 2025 | -20.67 Mn |
| Jun 30, 2025 | -20.67 Mn |
| Mar 31, 2025 | -21.08 Mn |
| Mar 31, 2025 | -21.08 Mn |
| Dec 31, 2024 | -12.09 Mn |
| Dec 31, 2024 | -12.09 Mn |
| Sep 30, 2024 | -12.31 Mn |
| Sep 30, 2024 | -12.31 Mn |
| Jun 30, 2024 | -15.19 Mn |
| Jun 30, 2024 | -15.19 Mn |
| Mar 31, 2024 | -15.72 Mn |
| Mar 31, 2024 | -15.72 Mn |
| Dec 31, 2023 | -16.01 Mn |
| Dec 31, 2023 | -16.01 Mn |